New research by Swansea University and Cambridge University has revealed the causes and devastating impacts of delays—that ...

One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.

Researchers from EMD Serono and global collaborators shared promising results from Cohort B of the phase II trial of the WILLOW study.

Inflammatory-type lesions and myelopathies found on MRI were significantly associated with attribution of neuropsychiatric events to systemic lupus erythematosus. Magnetic resonance imaging (MRI) ...

A team studied the differences between monogenic and nonmonogenic lupus nephritis and the predictors of end-stage kidney disease.

Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and remission in ...

Objective This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve ...

From subtle rashes to sun-safety strategies, Drs Maureen McMahon and John Edminister discuss how to recognize cutaneous lupus and protect patients from UV-triggered flares.

This article explores the complex roles of cytokine networks in the development and progression of autoimmune diseases.

Introduction Mycophenolic acid (MPA) is a primary immunosuppressive agent used in the treatment of lupus nephritis ... used for PubMed search were ((‘Lupus Erythematosus, Systemic’ (MeSH)) AND ...

The systemic lupus erythematosus (SLE) treatment pipeline is experiencing unprecedented expansion, driven by increasing disease awareness, rising pre ...

Flare and persistently active disease are prevalent in a multinational cohort study of patients with systemic lupus erythematosus, with some having persistently active disease without flare.